Comment on

• Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.

  Szmulewitz RZ, Peer CJ, Ibraheem A, Martinez E, Kozloff MF, Carthon B, Harvey RD, Fishkin P, Yong WP, Chiong E, Nabhan C, Karrison T, Figg WD, Stadler WM, Ratain MJ. Szmulewitz RZ, et al. J Clin Oncol. 2018 May 10;36(14):1389-1395. doi: 10.1200/JCO.2017.76.4381. Epub 2018 Mar 28. J Clin Oncol. 2018. PMID: 29590007 Free PMC article. Clinical Trial.
• Low-Fat Abiraterone Food Effect Is of Great Consequence.

  Tannock IF. Tannock IF. J Clin Oncol. 2018 Oct 20;36(30):3058-3059. doi: 10.1200/JCO.2018.79.2358. Epub 2018 Sep 6. J Clin Oncol. 2018. PMID: 30188783 No abstract available.
• There Is Now Compelling Evidence to Further Evaluate Lower Doses of Abiraterone Acetate in Men With Metastatic Prostate Cancer: It Should Be Safer, May Be as Effective and Less Expensive.

  Velho PI, Eisenberger MA. Velho PI, et al. J Clin Oncol. 2018 Oct 20;36(30):3059-3060. doi: 10.1200/JCO.2018.79.3166. Epub 2018 Sep 6. J Clin Oncol. 2018. PMID: 30188787 No abstract available.
• Low-Dose Abiraterone Regimen: Drug Monitoring Might Be the Key.

  Tiako Meyo M, Alexandre J, Goldwasser F, Blanchet B. Tiako Meyo M, et al. J Clin Oncol. 2018 Oct 20;36(30):3061-3062. doi: 10.1200/JCO.2018.79.3174. Epub 2018 Sep 6. J Clin Oncol. 2018. PMID: 30188788 No abstract available.
• Dose Reduction May Jeopardize Efficacy of Abiraterone Acetate.

  Woei-A-Jin FJSH, Van Nieuwenhuyse T, van Erp NP, Beuselinck B, Stroobants S, Moes DJAR, Osanto S, Spriet I. Woei-A-Jin FJSH, et al. J Clin Oncol. 2018 Oct 20;36(30):3062-3064. doi: 10.1200/JCO.2018.79.3182. Epub 2018 Sep 6. J Clin Oncol. 2018. PMID: 30188790 No abstract available.